G01N 2333/96497
Enkephalinase
Official title: Enkephalinase (3.4.24.11)
G01N2333/96497 (Enkephalinase) appears on 3 US grants and 5 published applications in this corpus.
Search patents in G01N- Granted patents
- 3
- Published applications
- 5
- Assignees
- 4
- Inventors
- 8
- Latest grant
- 12 Feb 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
By publication year.
Recent patents
- Neprilysin as heart failure prognostic marker12 Feb 2019US 10,203,341 B2Fundació Institut D'Investigació En CièNcies De La Salut Germans Trias I Pujol
- Treatment of pulmonary vascular remodeling with neprilysin24 Apr 2018US 9,950,044 B2The Regents of the University of Colorado, a body corporate
- Treatment of pulmonary vascular remodeling with neprilysin11 Nov 2014US 8,883,144 B2The Regents of the University of Colorado, a body corporate
- Anti-human cd10 antibodies for use in immunohistochemistry (ihc) protocols to diagnose cancer26 Dec 2024US 2024/0426827 A1Agilent Technologies, Inc.
- Neprilysin as heart failure prognostic marker7 Sep 2017US 2017/0254815 A1Fundació Institut D'Investigació En CièNcies De La Salut Germans Trias I Pujol
- Treatment of pulmonary vascular remodeling with neprilysin2 Apr 2015US 2015/0093373 A1The Regents of the University of Colorado, a body corporate
- Treatment of Pulmonary Vascular Remodeling With Neprilysin17 May 2012US 2012/0121573 A1The Regents of the University of Colorado, a body corporate
- Method for identifying bplp and opiorphin agonists or antagonists3 Dec 2009US 2009/0298109 A1Institut Pasteur
Most cited
By later US patents